1 / 7

Report Insights

Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES. Report Insights. Targeting unmet needs in the treatment of cancer or hematological malignancies through innovative drug development strategies have witnessed favorable outcomes

oriana
Download Presentation

Report Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Report Insights • Targeting unmet needs in the treatment of cancer or hematological malignancies through innovative drug development strategies have witnessed favorable outcomes • Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs - Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting in improved survival • However, eventually all patients relapse and new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) are required to further improve survival and quality of life of this group of patients

  2. Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Report Insights (Continued) • Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM) and Kyprolis (carfilzomib-CFZ) • A similar scenario is expected to unfold in the treatment of Recurrent/ Refractory MDS (RR-MDS, High-Risk MDS), and Relapsed/ Refractory AML (R/R AML) • Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature or nascent product or innovator company at a premium

  3. Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Report Coverage • Overview of the approved therapies for RRMM, NDMM, AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory patients • Competition and commercial opportunity in pursuing these therapy areas • Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them

  4. Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Table of Contents • Executive Summary • Disease Overview: MDS and AML • Current Standard of Care: MDS and AML • Unmet Need: AML • Late-Stage pipeline Targeting High-Risk or R/R MDS AND R/R AML • Late-Stage pipeline Targeting 1st-line Lower Risk MD • Key Milestones of Drugs For RRMDS/RRAML in 2014-2015 • Launch Timeline and Commercial Opportunity of Late-Stage Pipeline (RR MDS and RR AML) • Drivers of M&A/Licensing Deals in MDS/AML

  5. Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Report Details • Publish date:Feb 22, 2014 • Number of slides: 43 • Geographic coverage: Global • Available format: PDF, CD, Hardcopy • Price for Single User License: USD 1,500 • Price for Site License: USD 3,003 • Price for Global User License: USD 4,503 • Delivery Time: Within 1 business day • Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google Wallet, PayPal

  6. Interested in this report? To view more details regarding this premium market research report, Please click here For further information, get in touch with us: E-mail: support@researchonglobalmarkets.com Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600 About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports

More Related